Related Experiment Video
Updated: Sep 26, 2025
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
An Overview of siRNA Delivery Strategies for Urological Cancers
Nadia Halib1, Nicola Pavan2, Carlo Trombetta2
1Department of Basic Sciences & Oral Biology, Faculty of Dentistry, Universiti Sains Islam Malaysia, Kuala Lumpur 55100, Malaysia.
Abstract:
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
Insights
Small interfering RNA (siRNA) offers promising treatments for advanced urological cancers. Developing effective nano-delivery systems is crucial to protect fragile siRNAs and ensure their therapeutic efficacy in deep tissues.
Area of Science:
- Oncology
- Nanotechnology
- Molecular Biology
Background:
- Urological cancer treatments have advanced, but novel options are needed for advanced or resistant stages.
- Small interfering RNA (siRNA) shows therapeutic potential due to its ability to target specific pathological gene mRNAs.
- siRNAs are vulnerable in biological environments, necessitating protective delivery systems.
Purpose of the Study:
- To review the characteristics of siRNA and its potential in urological cancer therapy.
- To explore various nano-delivery systems designed for siRNA in urological applications.
- To categorize delivery systems based on materials and specific urological cancers.
Main Methods:
- Review of current literature on siRNA technology and urological cancers.
- Analysis of different nano-delivery systems, including polymeric nanoparticles, lipid nanoparticles, nanobubbles, and magnetic nanoparticles.
- Categorization of reported delivery systems by material and target urological cancer.
Main Results:
- siRNA holds significant promise for treating urological malignancies.
- Various nano-delivery systems are being investigated to overcome siRNA's fragility and improve tissue targeting.
- Examples of delivery systems are presented, classified by material and cancer type.
Conclusions:
- Effective delivery systems are essential for successful siRNA-based urological cancer therapies.
- Continued research into tailored nano-delivery systems will enhance siRNA's therapeutic application in urology.
- Nano-delivery systems are key to protecting siRNA integrity and function for deep tissue targeting.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...